A new FDA study found patients taking a high dose of Vioxx were three times more likely to have a heart attack. As a result, Merck & Co. is pulling the arthritis drug from the market.
Merck and Co. said it was voluntarily withdrawing its arthritis and pain medication Vioxx effective immediately after a study revealed an increased relative risk for cardiovascular problems.
In one of the largest prescription drug recalls in U.S. history, worldwide sales of the popular arthritis drug Vioxx were halted today after new data pointed to an increased patient risk for heart attacks and stroke.
Merck & Co. faces a rocky future after withdrawing its blockbuster arthritis pain drug Vioxx, a high-margin product that had accounted for almost 20% of its profit.
Merck & Co. withdrew its arthritis drug Vioxx globally after a colon cancer trial confirmed long-standing concerns the drug raises the risk of heart attack and stroke.
Taking more than 25 mg per day of Vioxx is linked to a tripling of the risk of heart attack, said a paper presented in the International Society for Pharmacoepidemiology Conference in Bordeaux, France.
Patients taking the popular arthritis drug Vioxx have three times the risk of heart attack as people not taking the medication, new research suggests.
One of the nation's biggest HMO's may be reconsidering it's endorsement of the popular prescription medication, Vioxx, after a new study found some potentially disturbing data.
A lawsuit recently filed against the makers of Vioxx alleges that Merck knew, or should have known, of the harmful side effects of Vioxx, but continued to market the drug without warning the public about the dangers. The lawsuits have been filed against Merck by the firm of Beasley, Allen, Crow, Met…
A lawsuit recently filed against the makers of Vioxx alleges that Merck knew, or should have known of the harmful side effects of Vioxx, but continued to market the drug without warning the public about the dangers. The lawsuit is one of 11 lawsuits that have been filed against Merck by the firm of …
